Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Short term Debt (2020 - 2025)

Mainz Biomed's Short term Debt history spans 5 years, with the latest figure at $1.0 million for Q4 2024.

  • For Q4 2024, Short term Debt fell 78.99% year-over-year to $1.0 million; the TTM value through Dec 2024 reached $1.0 million, down 78.99%, while the annual FY2024 figure was $1.0 million, 78.99% down from the prior year.
  • Short term Debt for Q4 2024 was $1.0 million at Mainz Biomed, down from $4.9 million in the prior quarter.
  • Across five years, Short term Debt topped out at $4.9 million in Q4 2023 and bottomed at $22754.0 in Q4 2021.
  • The 5-year median for Short term Debt is $32181.0 (2022), against an average of $1.2 million.
  • The largest annual shift saw Short term Debt soared 14998.97% in 2023 before it plummeted 78.99% in 2024.
  • A 5-year view of Short term Debt shows it stood at $24527.0 in 2020, then fell by 7.23% to $22754.0 in 2021, then surged by 41.43% to $32181.0 in 2022, then skyrocketed by 14998.97% to $4.9 million in 2023, then tumbled by 78.99% to $1.0 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Short term Debt are $1.0 million (Q4 2024), $4.9 million (Q4 2023), and $32181.0 (Q4 2022).